摘要:
A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
摘要:
Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides may also be used in methods that modulate B cell activation.
摘要:
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that bids to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
摘要:
The invention provides uses of polypeptides of soluble BR43x2 class receptors, and sequences substantially homologous thereto or orthologs thereof, as well as antibodies that bind to BR43x2 class soluble receptors in the manufacture of medicaments for inhibiting ztnf4 activity. The uses of the invention also extend to manufacture of medicaments for treating autoimmune diseases, such as systemic lupus erythematosus, myasthenia gravis, multiple sclerosis and rheumatoid arthritis, amongst others.
摘要:
There is provided a fusion protein consisting of a first portion and a second portion joined by a peptide bond, wherein said first portion consists of an amino acid sequence selected from: (i) amino acid residues 25-104 of SEQ ID NO: 6; (ii) amino acid residues 34-66 of SEQ ID NO: 6; (iii) amino acid residues 71-104 of SEQ ID NO: 6; and (iv) amino acid residues 34-66 and 71-104 of SEQ ID NO: 6; and said second portion is an immunoglobulin heavy chain constant region. There is also provided an antibody or antibody fragment that specifically binds to a polypeptide selected from SEQ ID NO: 59 or SEQ ID N: 60. There is also provided an antibody or antibody fragment that specifically binds to a ztnf4 polypeptide, for use in treating systemic lupus erythematosus in a mammal.
摘要翻译:提供了由肽键连接的第一部分和第二部分组成的融合蛋白,其中所述第一部分由选自以下的氨基酸序列组成:(i)SEQ ID NO:6的氨基酸残基25-104; (ii)SEQ ID NO:6的氨基酸残基34-66; (iii)SEQ ID NO:6的氨基酸残基71-104; 和(iv)SEQ ID NO:6的氨基酸残基34-66和71-104; 而第二部分是免疫球蛋白重链恒定区。 还提供了特异性结合选自SEQ ID NO:59或SEQ ID NO:60的多肽的抗体或抗体片段。还提供了特异性结合ztnf4多肽的抗体或抗体片段,用于治疗 系统性红斑狼疮在哺乳动物中。
摘要:
A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
摘要:
Soluble, secreted tumor necrosis factor receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise one cysteine-rich repeat that is homologous to other tumor necrosis factor receptors, such as transmembrane activator and CAML-interactor (TACI). The polypeptides may be used for detecting ligands, agonists and antagonists. The polypeptides may also be used in methods that modulate B cell activation.